278 related articles for article (PubMed ID: 21062269)
1. Monitoring of human papillomavirus vaccination.
Dillner J; Arbyn M; Unger E; Dillner L
Clin Exp Immunol; 2011 Jan; 163(1):17-25. PubMed ID: 21062269
[TBL] [Abstract][Full Text] [Related]
2. Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination.
Dillner J; Arbyn M; Dillner L
Clin Exp Immunol; 2007 May; 148(2):199-207. PubMed ID: 17437418
[TBL] [Abstract][Full Text] [Related]
3. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
Stanley M
Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine for the prevention of genital warts in males: profile report. demail@springer.com.
Garnock-Jones KP; Giuliano AR
Drugs R D; 2012 Dec; 12(4):235-8. PubMed ID: 23017129
[TBL] [Abstract][Full Text] [Related]
5. HPV vaccination in boys and men.
Stanley M
Hum Vaccin Immunother; 2014; 10(7):2109-11. PubMed ID: 25424825
[TBL] [Abstract][Full Text] [Related]
6. [The first vaccine against cancer: the human papillomavirus vaccine].
Bősze P
Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
[TBL] [Abstract][Full Text] [Related]
7. Nonavalent human papillomavirus vaccination as alternative treatment for genital warts.
Bossart S; Gabutti MP; Seyed Jafari SM; Hunger RE
Dermatol Ther; 2020 Jul; 33(4):e13771. PubMed ID: 32500585
[TBL] [Abstract][Full Text] [Related]
8. Reducing the health burden of HPV infection through vaccination.
Soper D
Infect Dis Obstet Gynecol; 2006; 2006 Suppl():83084. PubMed ID: 16967913
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus vaccine: widening the scope for cancer prevention.
No JH; Kim MK; Jeon YT; Kim YB; Song YS
Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574
[TBL] [Abstract][Full Text] [Related]
10. Vaccines for human papillomavirus infection: a critical analysis.
Nath AK; Thappa DM
Indian J Dermatol Venereol Leprol; 2009; 75(3):245-53; quiz 254. PubMed ID: 19439876
[TBL] [Abstract][Full Text] [Related]
11. Currently approved prophylactic HPV vaccines.
Harper DM
Expert Rev Vaccines; 2009 Dec; 8(12):1663-79. PubMed ID: 19943762
[TBL] [Abstract][Full Text] [Related]
12. The HPV infection in males: an update.
Giraldi G; De Luca d'Alessandro E
Ann Ig; 2012; 24(6):497-506. PubMed ID: 23234187
[TBL] [Abstract][Full Text] [Related]
13. Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques.
Wang Y; Liu Y; Liang S; Yin F; Zhang H; Liu Y
Papillomavirus Res; 2020 Dec; 10():100209. PubMed ID: 33197649
[TBL] [Abstract][Full Text] [Related]
14. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
15. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
Dunne EF; Datta SD; E Markowitz L
Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
[TBL] [Abstract][Full Text] [Related]
16. Health and economic implications of HPV vaccination in the United States.
Kim JJ; Goldie SJ
N Engl J Med; 2008 Aug; 359(8):821-32. PubMed ID: 18716299
[TBL] [Abstract][Full Text] [Related]
17. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the power of prevention: human papillomavirus vaccines.
Mayeaux EJ
Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s15-21. PubMed ID: 16520680
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
Broomall EM; Reynolds SM; Jacobson RM
Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
[TBL] [Abstract][Full Text] [Related]
20. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
